

Philippe Moreau

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11831822/philippe-moreau-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382
papers

38,201
citations

100
h-index

190
g-index

398
ext. papers

45,814
ext. citations

7.9
avg, IF

6.94
L-index

#	Paper	IF	Citations
382	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.. <i>ESMO Open</i> , 2022 , 7, 100403	6	4
381	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	10
380	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISM by clinical characteristics. <i>European Journal of Haematology</i> , 2022 , 108, 73-83	3.8	1
379	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221088458	5.7	
378	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101217	2.2	2
377	Extramedullary disease in multiple myeloma: a systematic literature review.. <i>Blood Cancer Journal</i> , 2022 , 12, 45	7	3
376	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.. <i>Leukemia</i> , 2022 ,	10.7	5
375	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.. <i>Blood</i> , 2022 , 139, 2747-2757	2.2	1
374	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022 , 6, e726	0.3	0
373	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 1582-1596	21.7	19
372	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021 , 35, 562-572	10.7	31
371	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021 , 5, e528	0.3	19
370	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021 , 194, 496-507	4.5	12
369	Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2021 , 17, 993-998	3.6	1
368	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021 , 137, 3616-3628	2.2	16
367	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021 , 22, e119-e130	21.7	33
366	Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. <i>Haematologica</i> , 2021 , 106, 2257-2260	6.6	3

365	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021 , 22, e105-e118	21.7	32
364	Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. <i>Blood</i> , 2021 , 138, 113-121	2.2	4
363	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 59	22.4	6
362	No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. <i>British Journal of Haematology</i> , 2021 , 194, 635-638	4.5	1
361	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1139-1149	2.2	23
360	Role of the HLA-G immune checkpoint molecule in pregnancy. <i>Human Immunology</i> , 2021 , 82, 353-361	2.3	4
359	The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. <i>Nature Immunology</i> , 2021 , 22, 769-780	19.1	23
358	Multiple myeloma triplet therapies: baseline characteristics and control groups - AuthorsReply. <i>Lancet, The</i> , 2021 , 397, 1621-1623	4.0	
357	Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. <i>Leukemia</i> , 2021 , 35, 3600-3603	10.7	2
356	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 2361-2371	4.0	46
355	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 801-812	21.7	35
354	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , 2021 , 106, 1725-1732	6.6	16
353	Standardization of F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 116-125	2.2	31
352	Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. <i>Bone Marrow Transplantation</i> , 2021 , 56, 395-399	4.4	3
351	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1005-1015	8.8	9
350	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. <i>Leukemia</i> , 2021 , 35, 1732-1744	10.7	3
349	Monoclonal antibodies as an addition to current myeloma therapy strategies. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 33-43	3.5	4
348	del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. <i>Blood</i> , 2021 , 137, 1192-1195	2.2	19

347	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2021 , 13, 143-154	3.8	4
346	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 142-154	21.7	22
345	Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. <i>EJHaem</i> , 2021 , 2, 48-55	0.9	2
344	Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching. <i>EJHaem</i> , 2021 , 2, 66-80	0.9	
343	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021 , 35, 1722-1731 ^{10.7}	10.7	18
342	Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 418-427	7.1	25
341	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021 , 384, 705-716	59.2	287
340	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. <i>Blood</i> , 2021 ,	2.2	5
339	Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 965-973	5.9	4
338	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). <i>Journal of Clinical Oncology</i> , 2021 , 39, 3602-3612	2.2	14
337	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2430-2442	2.2	18
336	The DNA methylation landscape of multiple myeloma shows extensive inter- and inpatient heterogeneity that fuels transcriptomic variability. <i>Genome Medicine</i> , 2021 , 13, 127	14.4	1
335	Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. <i>Expert Review of Hematology</i> , 2021 , 1-16	2.8	0
334	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>American Journal of Hematology</i> , 2021 , 96, E423-E427 ^{7.1}	7.1	3
333	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021 , 21, 993	4.8	1
332	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 1378-1390	21.7	15
331	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020 , 10, 111	7	3
330	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. <i>Clinical Epigenetics</i> , 2020 , 12, 163	7.7	1

329	Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes. <i>Cell Death and Disease</i> , 2020 , 11, 316	9.8	13
328	ImmunoPET in Multiple Myeloma-What? So What? Now What?. <i>Cancers</i> , 2020 , 12,	6.6	4
327	FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. <i>Cancers</i> , 2020 , 12,	6.6	1
326	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020 , 105, 35-46	3.8	4
325	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 35	7	10
324	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020 , 99, 1793-1804	3	3
323	Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1323-1333	1.9	6
322	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020 , 34, 2430-2440	10.7	30
321	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. <i>Advances in Therapy</i> , 2020 , 37, 1464-1478	4.7	4
320	Once-weekly (70 mg/m ²) vs twice-weekly (56 mg/m ²) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. <i>Cancer Medicine</i> , 2020 , 9, 2989-2996	4.8	9
319	First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 2308-2317	12.9	14
318	Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF- κ B pathway activation. <i>European Journal of Haematology</i> , 2020 , 105, 274-285	3.8	3
317	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e370-e380	14.6	98
316	Health-related quality-of-life results from the phase 3 OPTIMISM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1850-1859	1.9	4
315	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. <i>Leukemia</i> , 2020 , 34, 3019-3027	10.7	5
314	Timing the initiation of multiple myeloma. <i>Nature Communications</i> , 2020 , 11, 1917	17.4	36
313	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , 2020 , 34, 1875-1884	10.7	77
312	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020 , 34, 2000-2011	10.7	71

311	Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2254-2260	4.4	4
310	Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 775-783	2.2	139
309	Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. <i>Future Oncology</i> , 2020 , 16, 4347-4358	3.6	34
308	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2020 , 21, 207-221	21.7	281
307	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3107-3118	2.2	19
306	Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, 674-683	14.6	6
305	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3252-3260	2.2	41
304	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
303	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1630-1642	21.7	110
302	Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. <i>EJHaem</i> , 2020 , 1, 481-488	0.9	
301	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. <i>Cancers</i> , 2020 , 12,	6.6	4
300	Revealing the impact of structural variants in multiple myeloma. <i>Blood Cancer Discovery</i> , 2020 , 1, 258-273	3	28
299	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020 , 10, 91	7	36
298	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. <i>Leukemia</i> , 2020 , 34, 224-233	10.7	54
297	Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020 , 15, 129-139	3.9	11
296	Newly Diagnosed Myeloma in 2020. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-15	7.1	5
295	The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. <i>BMC Cancer</i> , 2019 , 19, 855	4.8	1
294	Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia Research</i> , 2019 , 83, 106172	2.7	9

293	Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial. <i>British Journal of Haematology</i> , 2019 , 187, 319-327	4.5	12
292	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019 , 380, 2104-2115	59.2	435
291	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 394, 29-38	40	383
290	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 522-530.e1	2	28
289	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2019 , 134, 421-431	2.2	80
288	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1657-1665	2.2	51
287	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 781-794	21.7	150
286	Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m vs. twice-weekly 27 mg/m carfilzomib (randomized A.R.R.O.W. study). <i>Leukemia</i> , 2019 , 33, 2934-2946	10.7	13
285	New insights in the treatment of patients with solitary bone plasmacytoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2810-2813	1.9	5
284	Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. <i>Blood Cancer Journal</i> , 2019 , 9, 38	7	37
283	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019 , 133, 1953-1963	2.2	63
282	Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. <i>Annals of Hematology</i> , 2019 , 98, 1435-1440	3	21
281	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. <i>Annals of Hematology</i> , 2019 , 98, 1441-1447	3	10
280	Interest of Pet Imaging in Multiple Myeloma. <i>Frontiers in Medicine</i> , 2019 , 6, 69	4.9	15
279	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019 , 186, e35-e39	4.5	10
278	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019 , 9, 23	7	23
277	Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e228-e237	2	4
276	F-FDG PET/CT in multiple myeloma: critical insights and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1048-1050	8.8	

275	Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. <i>Leukemia and Lymphoma</i> , 2019 , 60, 462-470	1.9	8
274	Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. <i>International Journal of Hematology</i> , 2019 , 110, 466-473	2.3	8
273	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019 , 381, 727-738	59.2	266
272	The Autoimmune Regulator (Aire) transactivates HLA-G gene expression in thymic epithelial cells. <i>Immunology</i> , 2019 , 158, 121-135	7.8	11
271	FDG PET in Multiple Myeloma 2019 , 27-38		2
270	Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patientsN selection and perspective. <i>OncoTargets and Therapy</i> , 2019 , 12, 5813-5822	4.4	16
269	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , 2019 , 134, 668-677	2.2	59
268	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 394, 2096-2107	40	253
267	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019 , 3, e163	0.3	23
266	Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. <i>Leukemia</i> , 2019 , 33, 313-318	10.7	10
265	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 253-264	40	131
264	Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 222-225	1.9	7
263	Ixazomib in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2018 , 14, 2013-2020	3.6	5
262	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018 , 73-96	0	1
261	Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. <i>Annals of Hematology</i> , 2018 , 97, 831-837	3	
260	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 121, 74-89	7	15
259	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018 , 32, 1542-1560	10.7	40
258	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. <i>Leukemia</i> , 2018 , 32, 2626-2635	10.7	31

257	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018 , 32, 2032-2036	10.7	7
256	Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria. <i>Leukemia and Lymphoma</i> , 2018 , 59, 583-589	1.9	1
255	Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1364-1374	1.9	6
254	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of SUVmax in the FDG-Avid Patients of the IMAJEM Study. <i>Clinical Cancer Research</i> , 2018 , 24, 5219-5224	12.9	16
253	Targeting Bcl-2 for the treatment of multiple myeloma. <i>Leukemia</i> , 2018 , 32, 1899-1907	10.7	72
252	Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. <i>Journal of Medical Economics</i> , 2018 , 21, 793-798	2.4	7
251	Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 49	22.4	25
250	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 985	7.1	31
249	Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 1389-1397	13.4	48
248	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2018 , 5, e563-e598	14.6	62
247	Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. <i>Blood</i> , 2018 , 132, 595-595	2.2	18
246	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , 2018 , 132, 1960-1960	2.2	1
245	Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8002-8002	2.2	10
244	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018 , 131, 301-310	2.2	151
243	Global Approaches in Myeloma: Critical Trials That May Change Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 656-661	7.1	2
242	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018 , 8, 109	7	97
241	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018 , 379, 1811-1822	59.2	268
240	Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 137	22.4	18

239	Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , 2018 , 103, 2088-2096	6.6	133
238	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2018 , 132, 2555-2563	2.2	37
237	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018 , 132, 2456-2464	2.2	191
236	BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. <i>Blood</i> , 2018 , 132, 2656-2669	2.2	37
235	Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. <i>Blood Advances</i> , 2018 , 2, 1633-1644	7.8	43
234	p53 regulates CD46 expression and measles virus infection in myeloma cells. <i>Blood Advances</i> , 2018 , 2, 3492-3505	7.8	12
233	A predictive model for risk of early grade B infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018 , 32, 1404-1413	10.7	28
232	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018 , 32, 2604-2616	10.7	90
231	Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. <i>Lancet Oncology</i> , 2018 , 19, 953-964	21.7	134
230	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e401-e419	2	37
229	The role of SLAMF7 in multiple myeloma: impact on therapy. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 67-75	5.1	8
228	Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. <i>Expert Review of Hematology</i> , 2017 , 10, 207-215	2.8	15
227	Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). <i>Haematologica</i> , 2017 , 102, e112-e114	6.6	32
226	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017 , 10, 229-237	2.8	24
225	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017 , 177, 404-413	4.5	50
224	Prognostic role of circulating exosomal miRNAs in multiple myeloma. <i>Blood</i> , 2017 , 129, 2429-2436	2.2	161
223	How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 153-170	7	27
222	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 571-582	4.5	39

221	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 547-560	4.5	38
220	Daratumumab for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 887-893	5.4	23
219	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017 , 99, 199-206	3.8	15
218	Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. <i>British Journal of Haematology</i> , 2017 , 179, 198-218	4.5	33
217	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017 , 376, 1311-1320	59.2	608
216	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017 , 92, 746-751	7.1	21
215	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2017 , 18, e206-e217	21.7	275
214	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2501-2504	1.9	16
213	Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 176, 783-795	4.5	30
212	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. <i>Blood</i> , 2017 , 130, 2401-2409	2.2	277
211	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017 , 130, 2610-2618	2.2	69
210	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 137	22.4	37
209	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3279-3289	2.2	361
208	Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAGEM Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2911-2918	2.2	172
207	Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. <i>International Journal of Molecular Sciences</i> , 2017 , 19,	6.3	1
206	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1327-1337	21.7	248
205	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. <i>Blood</i> , 2017 , 130, 2392-2400	2.2	182
204	Logic programming reveals alteration of key transcription factors in multiple myeloma. <i>Scientific Reports</i> , 2017 , 7, 9257	4.9	16

203	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017 , 178, 896-905	4.5	101
202	How I treat myeloma with new agents. <i>Blood</i> , 2017 , 130, 1507-1513	2.2	53
201	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017 , 102, 1767-1775	6.6	36
200	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. <i>British Journal of Haematology</i> , 2017 , 179, 66-74	4.5	12
199	Safety of ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 973-980	4.8	14
198	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017 , 117, 185-191	10.2	19
197	Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. <i>Frontiers in Physiology</i> , 2017 , 8, 149	4.6	12
196	New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. <i>Journal of Blood Medicine</i> , 2017 , 8, 107-121	2.3	17
195	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	19
194	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016 , 101, 872-8	6.6	18
193	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016 , 17, e328-e346	21.7	1155
192	Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. <i>Haematologica</i> , 2016 , 101, 1390-1397	6.6	51
191	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology,the</i> , 2016 , 3, e506-e515	14.6	98
190	Pomalidomide in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2016 , 12, 1975-83	3.6	7
189	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2833-2838	1.9	23
188	Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France. <i>Annals of Hematology</i> , 2016 , 95, 1307-13	3	2
187	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology, The</i> , 2016 , 17, 27-38	21.7	576
186	Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1546-59	1.9	19

185	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1544-57	2.2	204
184	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 35-48	3.8	19
183	Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016 , 128, 3309-3309	2.2	7
182	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. <i>Blood</i> , 2016 , 128, 488-488	2.2	21
181	Multiple myeloma--translation of trial results into reality. <i>Lancet, The</i> , 2016 , 388, 111-3	40	27
180	Carfilzomib versus bortezomib for relapsed or refractory myeloma - AuthorsReply. <i>Lancet Oncology, The</i> , 2016 , 17, e126	21.7	3
179	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016 , 22, 4350-4355	12.9	32
178	Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 1095-104	5.9	87
177	Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. <i>Haematologica</i> , 2016 , 101, 356-62	6.6	16
176	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016 , 76, 853-67	12.1	26
175	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 374, 1621-34	59.2	684
174	Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). <i>Leukemia and Lymphoma</i> , 2016 , 57, 2839-2847	1.9	8
173	How I treat extramedullary myeloma. <i>Blood</i> , 2016 , 127, 971-6	2.2	103
172	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016 , 127, 681-95	2.2	154
171	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016 , 127, 2955-62	2.2	463
170	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. <i>Blood</i> , 2016 , 127, 2569-74	2.2	167
169	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016 , 128, 497-503	2.2	117
168	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016 , 128, 1174-80	2.2	86

167	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3921-3930	2.2	58
166	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016 , 127, 713-21	2.2	99
165	The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. <i>Advances in Therapy</i> , 2016 , 33, 1896-1920	4.1	11
164	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 375, 1319-1331	59.2	930
163	Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 657-64	2.2	262
162	Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. <i>Cancer Biology and Therapy</i> , 2015 , 16, 60-5	4.6	17
161	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2863-9	2.2	976
160	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 737-48	3.5	43
159	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2015 , 125, 3100-4	2.2	41
158	Frontline therapy of multiple myeloma. <i>Blood</i> , 2015 , 125, 3076-84	2.2	206
157	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. <i>Blood</i> , 2015 , 125, 2095-100	2.2	64
156	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015 , 11, 1153-68	3.6	23
155	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015 , 100, 1334-9	6.6	34
154	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4767-73	12.9	150
153	Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. <i>Haematologica</i> , 2015 , 100, e56-9	6.6	29
152	Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>New England Journal of Medicine</i> , 2015 , 372, 142-52	59.2	928
151	Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 42-54	19.4	146
150	Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. <i>Haematologica</i> , 2015 , 100, e63-7	6.6	19

149	Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?. <i>Blood</i> , 2015 , 126, 2713-9	2.2	71
148	Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. <i>Blood</i> , 2015 , 125, 1411-7	2.2	78
147	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015 , 125, 2068-74	2.2	426
146	Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. <i>Haematologica</i> , 2015 , 100, e207-10	6.6	27
145	Multiple myeloma: from front-line to relapsed therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e504-11	7.1	39
144	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015 , 373, 621-31	59.2	935
143	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 519-30	2	31
142	HLA-G: An Immune Checkpoint Molecule. <i>Advances in Immunology</i> , 2015 , 127, 33-144	5.6	231
141	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015 , 100, 1327-33	6.6	63
140	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. <i>Lancet Haematology</i> , 2015 , 2, e516-27	14.6	129
139	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015 , 126, 1844-1844	2.2	4
138	Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015 , 126, 191-191	2.2	43
137	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , 2015 , 126, 28-28	2.2	22
136	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , 2015 , 126, 391-391	2.2	80
135	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015 , 126, 395-395	2.2	12
134	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01561507). <i>Blood</i> , 2015 , 126, 307-307	2.2	26
133	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8526-8526	2.2	5
132	Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. <i>Oncotarget</i> , 2015 , 6, 26922-34	3.3	17

131	Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment. <i>Oncotarget</i> , 2015 , 6, 37385-97	3.3	12
130	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 587-600	2.2	255
129	The effects of bortezomib on bone disease in patients with multiple myeloma. <i>Cancer</i> , 2014 , 120, 618-236.4	47	
128	Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2165-73	1.9	20
127	European perspective on multiple myeloma treatment strategies in 2014. <i>Oncologist</i> , 2014 , 19, 829-44	5.7	77
126	RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway. <i>BMC Cancer</i> , 2014 , 14, 437	4.8	15
125	Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 829-38	3.1	4
124	Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. <i>New England Journal of Medicine</i> , 2014 , 371, 906-17	59.2	565
123	Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Mylome. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2712-7	2.2	203
122	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1195-206	21.7	604
121	Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2173-80	2.2	128
120	Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. <i>Haematologica</i> , 2014 , 99, 1236-8	6.6	23
119	PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. <i>Blood</i> , 2014 , 124, 1626-36	2.2	101
118	Oral therapy for multiple myeloma: ixazomib arriving soon. <i>Blood</i> , 2014 , 124, 986-7	2.2	14
117	Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. <i>Haematologica</i> , 2014 , 99, e33-4	6.6	14
116	Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. <i>Journal of Cancer</i> , 2014 , 5, 248-52	4.5	9
115	The emerging role of carfilzomib combination therapy in the management of multiple myeloma. <i>Expert Review of Hematology</i> , 2014 , 7, 265-90	2.8	19
114	Elotuzumab for the treatment of multiple myeloma. <i>Future Oncology</i> , 2014 , 10, 949-56	3.6	9

113	All transplantation-eligible patients with myeloma should receive ASCT in first response. <i>Hematology American Society of Hematology Education Program, 2014, 2014, 250-4</i>	3.1	12
112	Immunophenotype of normal and myelomatous plasma-cell subsets. <i>Frontiers in Immunology, 2014, 5, 137</i>	8.4	43
111	The dual role of HLA-G in cancer. <i>Journal of Immunology Research, 2014, 2014, 359748</i>	4.5	72
110	An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. <i>Blood, 2014, 124, 176-176</i>	2.2	20
109	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood, 2014, 124, 2120-2120</i>	2.2	4
108	Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood, 2014, 124, 302-302</i>	2.2	11
107	Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. <i>Biology of Blood and Marrow Transplantation, 2013, 19, 445-9</i>	4.7	49
106	Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. <i>Experimental Hematology, 2013, 41, 1008-15</i>	3.1	18
105	Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. <i>Journal of Clinical Oncology, 2013, 31, 3279-87</i>	2.2	199
104	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The, 2013, 14, 1055-1066</i>	21.7	586
103	Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis. <i>European Journal of Cancer, 2013, 49, 411-5</i>	7.5	2
102	Initial treatment of transplant candidates with multiple myeloma. <i>Seminars in Oncology, 2013, 40, 585-91</i>	5.5	7
101	The translocation t(4;14) can be present only in minor subclones in multiple myeloma. <i>Clinical Cancer Research, 2013, 19, 4634-7</i>	12.9	12
100	Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du mylbme experience. <i>Journal of Clinical Oncology, 2013, 31, 2806-9</i>	2.2	84
99	Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Mylbme 2009-02. <i>Blood, 2013, 121, 1968-75</i>	2.2	173
98	VI. Autologous stem cell transplantation and maintenance therapy. <i>Hematological Oncology, 2013, 31 Suppl 1, 42-6</i>	1.3	1
97	Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). <i>Blood, 2013, 122, 3187-3187</i>	2.2	9
96	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood, 2013, 122, 767-767</i>	2.2	48

95	Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8542-8542	2.2	10
94	Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. <i>European Journal of Haematology</i> , 2012 , 88, 249-59	3.8	13
93	The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. <i>Seminars in Hematology</i> , 2012 , 49 Suppl 1, S33-46	4	47
92	Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 823-9	6.2	68
91	Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. <i>Cancer Research</i> , 2012 , 72, 4562-73	10.1	50
90	Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. <i>Blood Cells, Molecules, and Diseases</i> , 2012 , 48, 247-53	2.1	22
89	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , 2012 , 26, 149-57	10.7	580
88	Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2012 , 36 Suppl 1, S13-8	2.7	8
87	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012 , 120, 947-59	2.2	370
86	Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. <i>Haematologica</i> , 2012 , 97, 1925-8	6.6	108
85	European perspective on multiple myeloma treatment strategies: update following recent congresses. <i>Oncologist</i> , 2012 , 17, 592-606	5.7	43
84	Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1949-52	2.2	156
83	Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine</i> , 2012 , 366, 1782-91	59.2	848
82	Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow	2.2	162
81	Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1953-9	2.2	244
80	Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?. <i>Transplantation</i> , 2012 , 94, 295-301	1.8	12
79	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. <i>Blood</i> , 2012 , 120, 749-749	2.2	8
78	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. <i>Lancet Oncology</i> , 2011 , 12, 431-40	21.7	731

77	Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Haematologica</i> , 2011 , 96, 1504-11	6.6	46
76	Ultra high-risk myeloma: definition, identification, management. <i>Hematologie</i> , 2011 , 17, 145-149	0	
75	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. <i>Blood</i> , 2011 , 118, 1239-47	2.2	216
74	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. <i>Blood</i> , 2011 , 117, 2009-11	2.2	99
73	Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. <i>Blood</i> , 2011 , 117, 3041-4	2.2	98
72	ABT-737 is highly effective against molecular subgroups of multiple myeloma. <i>Blood</i> , 2011 , 118, 3901-10	2.2	89
71	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011 , 117, 6063-73	2.2	234
70	Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. <i>Blood</i> , 2011 , 118, 5752-8; quiz 5982	2.2	238
69	RIC alloSCT in MM: a long way to go. <i>Blood</i> , 2011 , 118, 2378-9	2.2	
68	PET-CT in MM: a new definition of CR. <i>Blood</i> , 2011 , 118, 5984-5	2.2	10
67	Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. <i>Cellular and Molecular Life Sciences</i> , 2011 , 68, 369-95	10.3	240
66	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011 , 117, 4701-5	2.2	323
65	Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1898-906	2.2	112
64	Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. <i>Recent Results in Cancer Research</i> , 2011 , 183, 189-206	1.5	18
63	Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). <i>Journal of Clinical Oncology</i> , 2010 , 28, 4630-4	2.2	336
62	Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. <i>Haematologica</i> , 2010 , 95, 311-9	6.6	123
61	Reply to J.C. Regeling et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e744-e745	2.2	
60	Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1209-14	2.2	125

59	International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4521-30 ²	2.2	136
58	Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4621-9	2.2	444
57	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. <i>Haematologica</i> , 2010 , 95, 1973-6	6.6	109
56	Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). <i>Blood</i> , 2010 , 115, 32-7	2.2	127
55	Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. <i>Blood</i> , 2010 , 116, 4777-82	2.2	99
54	Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02.. <i>Blood</i> , 2010 , 116, 310-310	2.2	35
53	A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2010 , 116, 312-312	2.2	5
52	Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study. <i>Blood</i> , 2010 , 116, 624-624	2.2	11
51	RREB-1 is a transcriptional repressor of HLA-G. <i>Journal of Immunology</i> , 2009 , 183, 6948-59	5.3	54
50	Prognostic significance of copy-number alterations in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4585-90	2.2	216
49	Non-classical transcriptional regulation of HLA-G: an update. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 2973-89	5.6	77
48	Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5720-6	2.2	131
47	HLA-G expression in the skin of patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 1230-4	4.4	30
46	Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 885-90	3.5	4
45	Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3664-70	2.2	322
44	Autologous hematopoietic stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine</i> , 2009 , 360, 2645-54	59.2	136
43	Bortezomib Plus Dexamethasone (VD) Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexamethasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).. <i>Blood</i> , 2009 , 114, 354-354	2.2	13
42	Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).. <i>Blood</i> , 2009 , 114, 529-529 ²	2.2	6

41	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008 , 111, 3968-77	2.2	260
40	Role of HLA-G in innate immunity through direct activation of NF-kappaB in natural killer cells. <i>Molecular Immunology</i> , 2008 , 45, 419-27	4.3	8
39	HLA-G: from biology to clinical benefits. <i>Trends in Immunology</i> , 2008 , 29, 125-32	14.4	288
38	Lenalidomide: a new therapy for multiple myeloma. <i>Cancer Treatment Reviews</i> , 2008 , 34, 283-91	14.4	30
37	IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. <i>Journal of Immunology</i> , 2008 , 181, 6837-42	5.3	29
36	HLA-G gene polymorphism in human placentas: possible association of G*0106 allele with preeclampsia and miscarriage. <i>Biology of Reproduction</i> , 2008 , 79, 459-67	3.9	82
35	Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Mylome. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4798-805	2.2	318
34	Beyond the increasing complexity of the immunomodulatory HLA-G molecule. <i>Blood</i> , 2008 , 111, 4862-70	2.2	256
33	Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. <i>Blood</i> , 2008 , 112, 3914-5	2.2	96
32	FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. <i>Haematologica</i> , 2008 , 93, 1269-71	6.6	58
31	Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. <i>Haematologica</i> , 2008 , 93, 1908-11	6.6	100
30	CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. <i>Leukemia Research</i> , 2008 , 32, 379-82	2.7	42
29	Frontline treatment of multiple myeloma in elderly patients. <i>Blood Reviews</i> , 2008 , 22, 303-9	11.1	9
28	Trogocytosis-based generation of suppressive NK cells. <i>EMBO Journal</i> , 2007 , 26, 1423-33	13	176
27	Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. <i>Seminars in Cancer Biology</i> , 2007 , 17, 413-21	12.7	85
26	Stem cell transplantation in multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 311-6	3.1	7
25	High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. <i>New England Journal of Medicine</i> , 2007 , 357, 1083-93	59.2	383
24	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Mylome. <i>Blood</i> , 2007 , 109, 3489-95	2.2	727

23	Role of bone marrow transplantation in the disease pathway of myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 163-9	7.3	3
22	Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients \geq 5 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01.. <i>Blood</i> , 2007 , 110, 75-75	2.2	37
21	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , 2006 , 108, 3289-94	2.2	556
20	Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. <i>Blood</i> , 2006 , 107, 397-403	2.2	81
19	Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. <i>Blood</i> , 2006 , 107, 3474-80	2.2	302
18	Lack of CD27 in myeloma delineates different presentation and outcome. <i>British Journal of Haematology</i> , 2006 , 132, 168-70	4.5	41
17	The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. <i>Haematologica</i> , 2006 , 91, 1234-40	6.6	140
16	Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. <i>Haematologica</i> , 2006 , 91, 1498-505	6.6	219
15	Evolving role of stem cell transplantation in multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 6, 89-95		8
14	Stem-cell transplantation in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 603-18	4.2	15
13	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. <i>American Journal of Hematology</i> , 2005 , 79, 319-28	7.1	971
12	HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. <i>Cancer Research</i> , 2005 , 65, 10139-44	10.1	207
11	Hematopoietic cell transplantation in multiple myeloma. <i>Current Opinion in Organ Transplantation</i> , 2004 , 9, 39-42	2.5	
10	HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. <i>Advances in Immunology</i> , 2003 , 81, 199-252	5.6	270
9	CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. <i>Blood</i> , 2003 , 102, 1070-1	2.2	141
8	Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. <i>Blood</i> , 2002 , 100, 1579-83	2.2	261
7	Comparison of 200 mg/m ² melphalan and 8 Gy total body irradiation plus 140 mg/m ² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Mylome 9502 randomized trial. <i>Blood</i> , 2002 , 99, 731-5	2.2	446
6	Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. <i>Blood</i> , 2001 , 97, 1566-71	2.2	269

5	IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. <i>International Immunology</i> , 1999 , 11, 803-11	4.9	340
4	Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. <i>British Journal of Haematology</i> , 1998 , 101, 766-9	4.5	188
3	Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection. <i>Cancer</i> , 1993 , 72, 3223-6	6.4	41
2	Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1992 , 30, 535-41	5.1	110
1	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. <i>American Journal of Hematology</i> ,	7.1	1